Short answer
TANDEM DIABETES CARE INC (TNDM) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
TANDEM DIABETES CARE INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 6, 2026 and furnished as Exhibit 99.1
- Investor focus: financial results and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 sales rose 6% to $254.6M, with U.S. growth 5% and international growth 7%
- Gross margin reached 57%, up from 52%, while adjusted EBITDA improved to $6.4M from negative $1.8M
- GAAP net loss narrowed to $21.2M from $52.4M, though free cash flow remained negative at $38.7M
- 2026 guidance reaffirmed: sales $1.065B-$1.085B and adjusted EBITDA margin 5%-6%
- Tubeless Mobi 510(k) submission and expanded Control-IQ+ compatibility support future product adoption and market reach
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TANDEM DIABETES CARE INC 8-K filings
Get the next TNDM 8-K as it lands
Follow TNDM for push alerts, or ask the research agent what this filing means.